Base de dados : LILACS
Pesquisa : E02.319.283.199 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 LILACS  
              next record last record
para imprimir
Texto completo
Texto completo
Id: biblio-912210
Autor: Bishnoi, Rohit; Shah, Chintan; Bejjanki, Harini; Bennett, Jeffery A; Reisman, David N.
Título: An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer
Fonte: Appl. cancer res;37:1-9, 2017. tab, ilus.
Idioma: en.
Resumo: Background: It is expected that about 65,000 new patients will be diagnosed with head and neck cancer in 2017 in the United States. Patients with recurrent or advanced or metastatic head and neck do not have good survival due to aggressive and recurrent nature of this cancer. Moreover, cumulative and residual toxicities from previous and ongoing treatments significantly impede quality of remaining part of their life. Currently available chemotherapeutic regimens for this group are derived from the treatments used for the potentially curable disease. These regimens and associated toxicity are obviously not the best matches for the treatment with palliative intent. We here present a retrospective study where we used dose-adjusted chemotherapy specifically for palliative treatment this sub-group of head and neck cancer patients. Methods: Study population was identified from the University of Florida, and IRB approval was obtained. We used currently available and approved chemotherapeutic agents (including Taxols, Platins, 5-Fluorouracil and Epidermal Growth Factor Receptor inhibitors) for treatment of head and neck cancer but dose-adjusted at approximate 50% dose of currently recommended doses. We then gave personalized doses for a prolonged period by titrating doses based on response and tolerability of each patient. Data was collected for treatment, response, side effects, and outcomes. KM analysis was performed for survival data. Results: Total of 32 patients were included in this study with a median age of 65.2 years and a median follow-up of 10.1 months. 62.5% (n = 20) had locally advanced disease and rest had metastatic disease. 37.5% (n = 12) had new disease while rest had recurrent cancer. Of 32 patients, 14 patients received TPF based while 18 patients received PFE based chemotherapy. Total of 270 chemotherapy cycles were delivered among these 32 patients. They received a median of 9 cycles (range 3­14) over a median of 6.2 months (range 1.8­21.1). With this treatment approach, we noted median progression-free survival of 14.0 months and median overall survival of 15.7 months. Notable grade 3 toxicities were generalized fatigue in 12.5% (n = 4), nausea/vomiting in 6.3% (n = 2), diarrhea in in 6.3% (n = 2), mouth soreness in 6.3% (n = 2), rash in 3.1% (n = 1), neutropenia in 18% (n = 6) and anemia in 15.6% (n = 5) while notable grade 4 toxicities were neutropenia and anaphylaxis in 3.1% (n = 1) patient each (AU)
Descritores: Cuidados Paliativos
Carcinoma de Células Escamosas/terapia
Tratamento Farmacológico
Administração Metronômica
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Limites: Humanos
Responsável: BR30.1 - Biblioteca

  2 / 2 LILACS  
              first record previous record
para imprimir
Texto completo
Id: lil-734396
Autor: Scharovsky, O. Graciela.
Título: Paradigmas, dosis y controversias en la terapéutica oncológica
Fonte: Medicina (B.Aires);74(4):337-339, ago. 2014.
Idioma: es.
Descritores: Administração Metronômica
Antineoplásicos/administração & dosagem
Carcinogênese/efeitos dos fármacos
-Doença Crônica
Reposicionamento de Medicamentos
Dose Máxima Tolerável
Limites: Animais
Tipo de Publ: Editorial
Responsável: AR1.2 - Instituto de Investigaciónes Epidemiológicas

página 1 de 1

Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde